Founder, President and Chief Executive Officer, Trucode, Inc.
Beth Seidenberg, MD
Beth Seidenberg, MD is the managing director of Westlake Village BioPartners, a venture capital firm that focuses on life sciences that she founded in September 2018. Dr. Seidenberg is also a General Partner at Kleiner Perkins, a venture capital firm, where she has primarily focused on life sciences investing since May 2005. Dr. Seidenberg was previously the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, Inc., a biotechnology company. In addition, Dr. Seidenberg was a senior executive in research and development at Bristol-Myers Squibb Company, a biopharmaceutical company, and Merck. Dr. Seidenberg received a BS from Barnard College and an MD from the University of Miami School of Medicine and completed her post-graduate training at The Johns Hopkins University, George Washington University and the National Institutes of Health.
Founding Managing Director, Westlake Village BioPartners; General Partner, Kleiner Perkins
Krishna Yeshwant, MD
Krishna Yeshwant, MD is a physician, programmer, and entrepreneur who has been working with GV (Google Ventures) since its inception. He first joined Google as part of the New Business Development team. Prior to Google he helped start an electronic data interchange company that was acquired by Hewlett-Packard and a network security company that was acquired by Symantec. He also co-authored the business plan for Diagnostics For All, which won both the Harvard Business School and MIT $100K business plan competitions. Dr. Yeshwant has a BS in computer science from Stanford University. He also earned an MD from Harvard Medical School, and MBA from Harvard Business School. He completed his residency at Brigham and Women’s Hospital in Boston, MA where he continues to practice. In addition to Trucode, his life sciences investments have included Editas Medicine and Flatiron Health.
General Partner, GV
Andrew Cheng, MD, PhD
Andrew Cheng MD, PhD is the President and Chief Executive Officer at Akero Therapeutics (AKRO). Dr. Cheng was formerly the Chief Medical Officer and Executive Vice President at Gilead Sciences. During his nearly 20 year tenure at Gilead, he was responsible for the clinical development for the HIV program resulting in 11 FDA/EMA approved products. His roles also included medical affairs and the creation of the development operations department (regulatory affairs, clinical operations, pharmacovigilance, project management, clinical pharmacology and biometrics), which covered clinical development support in multiple therapeutic areas including oncology, inflammation, respiratory, cardiovascular, HIV and liver diseases. He sits on the Board of Directors for Syntimmune, a clinical stage biotechnology company developing antibody therapeutics targeting FcRn that was acquired in 2018 by Alexion Pharmaceuticals. Dr. Cheng was board certified in internal medicine and completed his postgraduate training at the University of California, Los Angeles. He received his MD and PhD in cellular and molecular biology from Columbia University, where he received a NIH Medical Scientist Training Program fellowship.
Chief Executive Officer, Akero Therapeutics, Inc.
Joe Walton is a partner in Walton, Mitchell & Co. (WM), a private investment firm. Founded in 1993 and initially focused on oil and gas exploration, WM now invests in early-stage technology and life sciences companies. WM was a founding investor in PNA Innovations, Inc. where Mr. Walton served as Chairman until its acquisition by Trucode. Mr. Walton has experience as a private company investor, director, consultant and currently serves as on the Boards of Delta Wing Technologies Group, Powercast, and Blume Honey Water. He has been investing in start-up companies since 1979. He currently serves as Trustee of several non-profit entities in Pittsburgh including, the Children’s Hospital of Pittsburgh of UPMC and The Carnegie Hero Fund Commission. He received a BA from Williams College and MBA from The Graduate School of Business at The University of Texas at Austin.
Partner, Walton, Mitchell & Co.
Marshall Fordyce, MD
Marshall Fordyce, MD is Co-founder, President and Chief Executive Officer of Trucode. He brings more than 10 years of experience leading teams in drug discovery, development, clinical translation, and commercialization. Prior to founding Trucode, he was an entrepreneur in residence at Kleiner Perkins. Previously, Dr. Fordyce served as Senior Director of Clinical Research at Gilead Sciences, where he contributed to seven new drug approvals and served as Project Lead for Gilead’s highly successful TAF/GENVOYA development program. With subspecialty training in infectious disease from Columbia P&S, Dr. Fordyce was previously Chief Resident at NYU Bellevue and spent two years as translational research fellow at Rockefeller University. Dr. Fordyce has been an advisor to Google X and to several private biotech companies. He currently serves on the Board of Directors of the Albert and Mary Lasker Foundation. He received his BA from Harvard University and his MD from Harvard Medical School.
Founder, President and Chief Executive Officer, Trucode Gene Repair, Inc.